IP Watch on January 25 published GlaxoSmithKline’s position statement on the Anti-Counterfeiting Trade Agreement. The company generally supports the agreement, as it “fully supports any efforts aimed at ensuring strong enforcement of IPRs.” GSK would have preferred to have seen the inclusion of patents in the civil enforcement, but it has “no objection to the omission of criminal sanctions for patent infringers” and “no objection to the exclusion of in-transit patent provisions.”
Follow
Free to Share
Comments on:
- An error has occurred, which probably means the feed is down. Try again later.
Civil Society Documents
- An error has occurred, which probably means the feed is down. Try again later.
Comments on:
- An error has occurred, which probably means the feed is down. Try again later.
industry | infojustice
- Aspen Doesn’t Want You to Own Your Own Casebooks
- Still Profitable After All These Years
- Recording Industry Reports Growth from User-Generated Content and New Projects in Emerging Economies
- EC Trade Negotiators and Industry Discuss How to ‘Re-Educate’ Public About Intellectual Property Rights (talk about employment)
- Witnesses at U.S. Trade Hearing Offer Opinions (and Warnings) on Intellectual Property in Upcoming Negotiations with the EU